PCR Journal Club

The primary objective of the study was to assess whether an IVUS-based stent optimization provided an incremental value in terms of vessel-related adverse event occurrence in patients presenting with low post-PCI FFR (<0.90).

The results of this study show that at 2-year follow-up HBR patients undergoing PCI with a polymer-based zotarolimus-eluting stent & 1-month DAPT had similar outcomes in terms of both safety & efficacy to those with a polymer-free biolimus A9-coated stent.

This trial aimed to assess the safety and efficacy of a biolimus coated balloon in patients with small vessel CAD undergoing PCI.

This study aimed to determine the effectiveness of jailing a wire in the side branch of a bifurcation lesion to prevent side branch compromise during provisional main vessel stenting when a one-stent in bifurcation PCI technique is adopted.

The recently published ADAPT-DES sub-study addressed the question of early and long-term impact of contrast-associated acute kidney injury (CA-AKI) on net adverse clinical events. In addition, the authors defined risk factors for the development of CA-AKI in all-comers using contemporary PCI techniques.

CRUNCH registry aimed to investigate the safety and efficacy of intravascular lithotripsy in the setting of resistant stent under expansion due to underlying calcific plaques.

The objective of this analysis was to evaluate the impact of residual ischemia detected by post-PCI iFR on clinical outcomes and on residual-angina at the 12-month follow-up of the DEFINE PCI study.

To further investigate the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary HBR population, a pre-specified analysis of the TWILIGHT trial, TWILIGHT-HBR, was conducted by using the Academic Research Consortium (ARC) criteria for HBR.

The purpose of the present investigation was to revisit all stent expansion indexes to identify the best predictor of 2-year percutaneous coronary intervention (PCI) lesion-specific outcome measures (i.e. clinically-driven target lesion revascularization [TLR] or definite stent thrombosis) using the ADAPT-DES IVUS substudy cohort.

This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.